garcinol has been researched along with gemcitabine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ali, S; Banerjee, S; Deryavoush, T; Gupta, S; Parasramka, MA; Sarkar, FH | 1 |
Akhtar, S; David, D; Geamanu, A; Goja, A; Gupta, SV; Razalli, NH; Saadat, N; Shen, Y | 1 |
2 other study(ies) available for garcinol and gemcitabine
Article | Year |
---|---|
Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspases; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Interleukin-8; Matrix Metalloproteinase 9; Microarray Analysis; MicroRNAs; NF-kappa B; Pancreatic Neoplasms; Phenotype; Signal Transduction; Terpenes; Vascular Endothelial Growth Factor A; Wound Healing | 2013 |
Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Deoxycytidine; Dietary Supplements; Gemcitabine; Genes, p53; Genes, ras; Humans; Magnetic Resonance Imaging; Male; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; S100 Calcium Binding Protein beta Subunit; Smad4 Protein; Survival Rate; Terpenes | 2018 |